Results

1–10 of 391 results for AMD

Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2023
Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2023
Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2023
Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Rajeev H. Muni, MD, MSC, FRCS(C), FASRS
Annual Meeting Talks
2023
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2023
Ellipsoid Zone Integrity Preservation and Characterization of Ellipsoid Zone Integrity Features in the GATHER 1 Phase 2/3 Study
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2023
Intravitreal Avacincaptad Pegol in Geographic Atrophy: Post-Hoc Analysis of Vision Loss From the GATHER Clinical Program
Carl J Danzig, MD
Annual Meeting Talks
2023